Sabela Lens
Research group
- Viral, genetic and immune-mediated liver diseases Group leader (R4)
About me
As a hepatology specialist, I focus my research on viral hepatitis. After completing my PhD at the University of Barcelona and a postdoctoral fellowship at University College London (United Kingdom), I now lead a clinical and translational program dedicated to investigating the interaction between hepatitis viruses and the host immune response. I also promote a public health line aimed at the elimination of viral hepatitis. I am the principal investigator of several competitive research projects, an associate professor at the University of Barcelona, actively participate in national and international scientific societies, and have received several awards in hepatology
Featured publications
-
Tracking B cell immunity during perturbation of hepatitis B infection induced by treatment withdrawal
Authors:Reference: GUT 2025. -
Incidence and Clinical Significance of Recompensation After HCV Cure
Authors:Reference: Clinical Gastroenterology and Hepatology 2025. -
Determinants of HBsAg Loss After Nucleos(t)ide Discontinuation in a Prospective Cohort of HBeAg-Negative Caucasian Patients
Authors:Reference: LIVER INTERNATIONAL 2025. -
HBV Suppression by Nucleos(t)ide Analogues Reduces PD-1 Expression on Liver-Resident T Cells
Authors:Reference: LIVER INTERNATIONAL 2025. -
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Authors:Reference: ALIMENTARY PHARMACOLOGY & THERAPEUTICS 2024. -
Tissue CD14+CD8+ T cells reprogrammed by myeloid cells and modulated by LPS
Authors:Reference: NATURE 2023. -
Non-invasive tests for clinically significant portal hypertension after HCV cure
Authors:Reference: JOURNAL OF HEPATOLOGY 2022. -
HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates
Authors:Reference: JHEP Rep 2022. -
Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients
Authors:Reference: JOURNAL OF HEPATOLOGY 2021. -
Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension
Authors:Reference: JOURNAL OF HEPATOLOGY 2020.
Featured Projects
-
Análisis transcriptómico espacial de las interacciones virus-huésped y la respuesta al tratamiento en la hepatitis crónica Delta (SPACE-D)
Principal investigator: Sabela Lens García, Xavier Forns BernhardtFunder: Instituto de Salud Carlos III (ISCIII)Code: PI25/01234Duration: 01/01/2026 - 31/12/2028 -
TherVacB: A therapeutic vaccine to cure hepatitis B
Principal investigator: Xavier Forns BernhardtFunder: European CommissionCode: 848223Duration: 01/01/2020 - 31/12/2024 -
Eliminación de VHC y diagnóstico y vinculación de pacientes VHD en el área sanitariadel Hospital Clínic de Barcelona (HepCD-Clinic)
Principal investigator: Sabela Lens GarcíaFunder: Asociación Española para el Estudio del Hígado - Gilead SciencesDuration: 01/01/2026 - 31/12/2027 -
Bulevirtide for Hepatitis Delta: clinical impact on liver disease and non-invasive correlates with portal hypertension
Principal investigator: Sabela Lens GarcíaFunder: Gilead SciencesDuration: 01/01/2026 - 31/12/2027 -
Red C17 Viral Hepatitis Care 2030: Innovación en la detección y equidad asistencial en hepatitis vírica
Principal investigator: Sabela Lens GarcíaFunder: Generalitat de CatalunyaDuration: 01/01/2026 - 31/12/2027
